Search - tctmd.com

Displaying 861 - 880 of 2429

Sort: Relevancy | Date

Presentation

Newer-Generation Ultrathin-Strut DES vs Older Second-Generation Thicker-Strut DES for CAD

July 11, 2018

News Daily News

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Michael O'Riordan

July 10, 2018

News Daily News

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

Michael O'Riordan

July 06, 2018

News Daily News

New Review Probes Possibility of CVD Prevention Without Aspirin

Michael O'Riordan

July 04, 2018

Podcast TCTMD Talking Points

PLATINUM DIVERSITY: Increased Risk of Cardiac Events After PCI in Minority Women

July 04, 2018

News Daily News

Norepinephrine Bests Epinephrine in Battle of the Vasopressors in Cardiogenic Shock

L.A. McKeown

July 03, 2018

News Daily News

Once Again, ISCHEMIA Trial Feels the Squeeze

Michael O'Riordan

June 29, 2018

News Daily News

New Estimates of Bleeding Risks May Help CVD Prevention

Todd Neale

June 27, 2018

News Daily News

CVD Prevention and Control Remains a Challenge in India

L.A. McKeown

June 26, 2018

Podcast TCTMD Talking Points

DARE: A Randomized Trial of a Drug-Eluting Balloon vs a Metallic DES in Patients With Coronary Artery In-Stent Restenosis

June 20, 2018

News Daily News

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

Yael L. Maxwell

June 15, 2018

News Daily News

Platelet Reactivity Linked With Ischemic Stroke Risk Post-DES Implantation: ADAPT-DES Substudy

Yael L. Maxwell

June 08, 2018

News Daily News

Liability Reform Changes How Docs Manage Suspected Coronary Artery Disease

Michael O'Riordan

June 07, 2018

News Conference News EuroPCR 2018

ORBITA Deep Dive Highlights Treatment Choices, Social Media, and Ethics

Michael O'Riordan

May 31, 2018

News Conference News EuroPCR 2018

Ticagrelor Doesn’t Carry Any Off-Target Effects Compared With Clopidogrel, Prasugrel

Yael L. Maxwell

May 30, 2018

News Conference News EuroPCR 2018

‘Transient’ STEMI Patients Can Be Immediately Treated or Safely Deferred to Next Day

Michael O'Riordan

May 24, 2018

News Conference News EuroPCR 2018

Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions

Michael O'Riordan

May 23, 2018

Podcast TCTMD Talking Points

DAPT STEMI: A Randomized Trial of 6-Month vs 12-Month DAPT After DES Implantation in STEMI

May 23, 2018

News Conference News EuroPCR 2018

FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis

Michael O'Riordan

May 22, 2018

News Daily News

One in Five ACS Patients Does Not Fill P2Y12 Inhibitor Prescription After PCI

Michael O'Riordan

May 21, 2018

Advertisement

Newer-Generation Ultrathin-Strut DES vs Older Second-Generation Thicker-Strut DES for CAD

ORBITA Redux: Lancet Correspondence Takes Talk of the Sham-Controlled PCI Trial to Further Heights

Rivaroxaban Offers Net Reduction in Fatal or Irreversible Events in ACS: ATLAS ACS-2 TIMI-51

New Review Probes Possibility of CVD Prevention Without Aspirin

PLATINUM DIVERSITY: Increased Risk of Cardiac Events After PCI in Minority Women

Norepinephrine Bests Epinephrine in Battle of the Vasopressors in Cardiogenic Shock

Once Again, ISCHEMIA Trial Feels the Squeeze

New Estimates of Bleeding Risks May Help CVD Prevention

CVD Prevention and Control Remains a Challenge in India

DARE: A Randomized Trial of a Drug-Eluting Balloon vs a Metallic DES in Patients With Coronary Artery In-Stent Restenosis

Serial CTA Shines a Light on Statin Effects in Subclinical CAD

Platelet Reactivity Linked With Ischemic Stroke Risk Post-DES Implantation: ADAPT-DES Substudy

Liability Reform Changes How Docs Manage Suspected Coronary Artery Disease

ORBITA Deep Dive Highlights Treatment Choices, Social Media, and Ethics

Ticagrelor Doesn’t Carry Any Off-Target Effects Compared With Clopidogrel, Prasugrel

‘Transient’ STEMI Patients Can Be Immediately Treated or Safely Deferred to Next Day

Modest Benefit of PCI Over Medical Therapy in Patients With ‘Grey Zone’ FFR Lesions

DAPT STEMI: A Randomized Trial of 6-Month vs 12-Month DAPT After DES Implantation in STEMI

FFR-Guided PCI Reduces Risk of Death/MI Compared With Medical Therapy: Pooled Analysis

One in Five ACS Patients Does Not Fill P2Y12 Inhibitor Prescription After PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content